Novel Antithrombotic Agents in Vascular Surgery

Kroll MH , Harris TS , Moake JL , Handin RI , Schafer AI von Willebrand factor binding to platelet GP Ib initiates signals for platelet activation. J Clin Invest 88:1568, 1991.

Harker LA , Maraganore JM , Hirsh J. Novel antithrombotic agents. In Coleman RW , Hirsh J , Marder VJ , Salzman EW , eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd ed. New York: McGraw-Hill , 1994, pp 1638-1660.

Swords NA , Mann KG The assembly of the prothrombinase complex of adherent platelets. Arterioscler Thromb 13:1602, 1993.

Broze GJ Jr. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol 29:159, 1992.

Antiplatelet Trialist's Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 298:320, 1988.

ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected myocardial infarction. Lancet 2:349, 1988.

Fuster V. , Dyken ML , Vokonas PS , Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. Circulation 87:659-675, 1993.

Hirsh J. , Dalen J. , Fuster V. , Harker LB , Salzman EW Aspirin and other platelet-active drugs: The relationship between dose, effectiveness, and side effects. Chest 102(Suppl): 327S, 1992.

Buchanan MR , Dejana E. , Cazenave JP , Richardson M. , Mustard JF , Hirsh J. Differences in inhibition of PGI2 production by aspirin in rabbit artery and vein segments. Thromb Res 20:447, 1980.

Dyken ML Controversies in stroke: Past and present. The Willis lecture. Stroke 24:1251, 1993.

Clark RJ , Mayo G. , Price P. , Fitzgerald GA Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 325:1137, 1991 .

Keimowitz RM , Pulvermacher G. , Mayo G. , Fitzgerald DJ Transdermal modification of platelet function: A dermal aspirin preparation selectively inhibits platelet cyclooxygenase and preserves prostacyclin biosynthesis. Circulation 88:556, 1993.

O'Brian JR Ticlopidine. Haemostasis 13(Suppl 1):1, 1983.

Gent M. , Easton JD , Hachinski VC , Panak E. , Sicurella J. , Blakely JA , Ellis DJ , Harrison JW , Roberts RS , Turpie AGG. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke . Lancet 1:1215, 1989.

Hass WK , Easton JD , Adams JR , Pryuse-Phillips W. , Molony BA , Anderson S. , Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 321:501, 1989.

Saltiel E. , Ward A. Ticlopidine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs 34:222, 1987.

Mills DCB , Puri R. , Hu CJ , Minniti C. , Grana G. , Freedman MD , Coleman RF , Coleman, RW Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arteriosclerosis Thromb 12:430, 1992.

Sakariassen KS , Fressinaud E. , Girma JP , Meyer D. , Baumgartner HR Role of platelet membrane glycoproteins and vWf in adhesion of platelets to subendothelium and collagen. Ann NY Acad Sci 516:52, 1987.

Kieffer N. , Phillips DR Platelet membrane glycoproteins: Functions in cellular interactions . Ann Rev Cell Biol 6:329, 1990.

Hynes RO Integrins: Versatility, modulation, and signaling in cell adhesion . Cell 69:11, 1992.

Krupski WC , Bass A. , Cadroy Y. , Kelly AB , Harker LA , Hanson SR Antihemostatic and antithrombotic effects of monoclonal antibodies against wWf in nonhuman primates. Surgery 112:433, 1992.

Du X. , Beutler L. , Ruan C. , Castaldi PA , Berndt MC Glycoprotein Ib and glycoprotein IX are fully complexed in the intact platelet membrane. Blood 5:1524, 1987.

Plow EF , McEver RP , Coller BS , Woods VL Jr , Margureie GA , Ginsberg MH Related binding mechanisms for fibrinogen, fibronectin, vWf, and thrombospondin on thrombin-stimulated human platelets. Blood 66:724, 1985.

Dennis MS , Henzel WJ , Pitti RM , Lipari MT , Napier MR , Deisher TA , Bunting S. , Lazurus RA Platelet glycoprotein IIb-IIIa protein antagonist from snake venoms: Evidence for a family of platelet-aggregation inhibitors. Proc Natl Acad Sci USA 87:2471, 1989.

Krupski WC , Bass A. , Kelly AB , Ruggeri ZM , Harker LA , Hanson SR Interruption of vascular thrombosis by bolus antiplatelet glycoprotein IIb-IIIa monoclonal antibodies in baboons. J Vasc Surg 17:294, 1993.

Topol EJ , Plow EF Clinical trials of platelet receptor inhibitors. Thromb Haemost 70:94, 1993.

Kleiman NS , Ohman EM , Keriakes DJ , Ellis SG , Weisman HF , Toplo EJ Profound platelet inactivation with 7E3 shortly after thrombolytic therapy for acute myocardial infarction: Preliminary results of the TAMI 8 trial. Circulation 84(Suppl II):II-522, 1991.

Bush LR , Holahan MA , Kanovsky SM , Mellott MJ , Garsky VM , Gould RJ Antithrombotic profile of echistatin, a snake venom peptide and platelet fibrinogen receptor antagonist in the dog. Circulation 80(Suppl II):II-23, 1989.

Savage B. , Marzec UM , Chao BH , Harker LA , Maraganore JM , Ruggeri ZM Binding of the snake venom-derived proteins applaggin and echistatin to the arginine-glycine-aspartic acid recognition site(s) on paltelet glycoprotein IIb-IIIa complex inhibits receptor function. J Biol Chem 265:11766, 1990.

Rubin BG , McGraw DJ , Sicard GA , Santoro SA. New RGD analogue inhibits human platelet adhesion and aggregation and eliminates platelet deposition on canine vascular grafts. J Vasc Surg 15:683-692, 1992.

Hanson SR , Kotze HF , Harker LA , Scarborough RM , Charo IF , Phillips DR Potent antithrombotic effects of novel peptide antagonists of platelet glycoprotein IIb-IIIa. Thromb Haemost 65:81, 1991.

Haskel EJ , Adams SP , Feigen LP , Saffitz JE , Gorczynski RJ , Sobel BE , Abendschein DR Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb-IIIa receptors . Circulation 80:1775, 1989.

Wilcox JN Thrombin and other potential mechanisms underlying restenosis. Circulation 84:432-435, 1991.

Maraganore JM Thrombin, thrombin inhibitors, and the arterial thrombotic process. Thromb Haemost 70:208, 1993.

Kelly AB , Marzec UM , Krupski W. , Bass A. , Cadroy Y. , Hanson SR , Harker LA Hirudin interruption of heparin-resistant arterial thrombus formation in baboons . Blood 77:1006, 1991.

Topol EJ , Bonan R. , Jewitt D. , Sigwart U. , Kakkar W. , Rothman M. , deBono D. , Ferguson J. , Willerson JT , Strony J. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 87:1622, 1993.

Maraganore JM Thrombin, thrombin inhibitors, and the arterial thrombotic process. Thromb Haemost. 70:208, 1993.

Kelly AB , Maraganore JM , Bourdon P. , Hanson SR , Harker LA Antithrombotic effects of synthetic peptides targeting different functional domains of thrombin. Proc Natl Acad Sci USA 89:6040, 1992.

Yasuda T. , Gold HK , Yaoita H. , Leinbach RC , Guerrero JL , Jang IK , Holt R. , Fallon JT , Collen D. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb-IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in canine preparation. J Am Coll Cardiol 16:714, 1990.

Kotze H. , Lumsden A. , Harker J. , Hanson S. In vivo antithrombotic effects of local vs systemic therapy with potent antithrombins . Circulation 82(Suppl III):III-659, 1990.

Imura Y. , Stassen JM , Collen D. Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in hamster femoral vein platelet-rich mural thrombosis model . J Pharmacol Exp Ther 261:895, 1992.

Coughlin SR Thrombin receptor structure and function. Thromb Haemost 70:184, 1993.

Wilcox J. , Ollerenshaw J. , Zhong C. , Hayzer DJ , Rodriguez J. , Subramanian RR , Harker LA , Hanson SR , Kelly AB , Runge MS Localization of thrombin receptor expression in proliferating smooth muscle cells in vivo. Circulation 86(Suppl II):II-50, 1992.

Esmon CT The protein C anticoagulant pathway. Arteriosclerosis Thromb 12:135, 1992.

Solis MM , Cook C. , Cook J. , Glaser C. , Light D. , Morser J. , Yu S. , Fink L. , Eidt JF Intravenous recombinant soluble human thrombomodulin prevents venous thrombosis in a rat model. J Vasc Surg 14:599, 1991.

Gruber A. , Hanson SR , Kelly A. , Tan BS , Bang N. , Griffin JH , Harker LA Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. Circulation 82:578, 1990.

Gruber A. , Hanson SR , Kelly AB , Yau BS , Bang N. , Griffin JH , Harker LA Inhibition of thrombus formation by activated recombinant protein C in primate model of arterial thrombosis. Circulation 82:578, 1990.

Bock LC , Griffin LC , Latham JA , Vermaas EH , Toole JJ Selection of single-stranded DNA molecules that bind and inhibit human thrombin . Nature 355:564, 1992.

Andree HA , Stuart MC , Hermens WT , Reutelingsperger CP , Hemker HC , Frederik PM , Willems GM Clustering of lipid-bound annexin V may explain its anticoagulant effect. J Biol Chem 267(25):17907, 1992.

Thiagarajan P. , Tait JF Binding of annexin V/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. J Biol Chem 265(20):17420, 1990.

Schaffer LW , Davidson JT , Vlasuk GP , Siegl PKS. Antithrombotic efficacy of recombinant tick anticoagulant peptide: A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. Circulation 84:1741, 1991.

Dunwiddie CT , Nutt EM , Vlasuk GP , Siegl PK , Schaffer LW Anticoagulant efficacy and immunogenicity of the selective factor Xa inhibitor antistasin following subcutaneous administration in the rhesus monkey. Thromb Haemost 67:371, 1992.

Girard FJ , MacPhail LA , Likert KM , Novotny WF , Miletich JP , Broze GJ Inhibition of factor VIIa-tissue factor coagulation activity by a hybrid protein . Science 248:1421, 1990.

Haskel EJ , Torr SR , Day KC , Palmier MO , Wun TC , Sobel BE , Abendschein DR Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation 84:821, 1991.

Colman RW , Marder VJ , Salzman EW , Hirsh J. Overview of hemostasis. In Colman RW , Coleman RW , Hirsh J , Marder VJ , Salzman EW , eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd ed. New York: McGraw,-Hill, 1994, pp 3-19.

Belch JJF , Meek DR , Lowe GDO , Campbell HF , Young AB , Forbes CD , Prentice CR Subcutaneous ancrod in prevention of deep vein thrombosis after hip replacement surgery. Thromb Res 25:23, 1982.

Cole CW , Bormanis J. Ancrod : A practical alternative to heparin. J Vasc Surg 8:59, 1988.

Demers C. , Ginsberg JS , Brill-Edwards P. , Panju A. , Warkentin TE , Anderson DR , Turner C. , Kelton JG Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia . Blood 78:2194, 1991.

Anderson DR , O'Brian BJ , Lenine MN , Roberts R. , Wells PS , Hirsh J. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep venous thrombosis after total hip arthroplasty. Ann Intern Med 119:1105, 1993.

Hirsh J. , Levin MN Low molecular weight heparin. Blood 79:1, 1992.

Hull R. , Raskob G. , Pineo G. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 326:975, 1992.

Koppenhagen K. , Adolf J. , Matthes M. , Troster E. , Roder JD , Haas S. , Fritsche HM , Wolf H. Low molecular weight heparin and prevention of postoperative thrombosis in abdominal surgery. Thromb Haemost 67:627, 1992.

Fareed J. , Hoppensteadt DA , Walenga JM Current perspectives on low molecular weight heparins. Semin Thromb Hemost 19(Suppl I): 1, 1993.

Goodnight SH Fish oil and vascular disease. Trends Cardiovasc Med 1:112, 1991.

Goodnight SH The effects on n-3 fatty acids on atherosclerosis and the vascular response to injury. Arch Path Lab Med 117:102, 1993.

Goodnight SH Effects of dietary fish oil and omega-3-fatty acids on platelets and blood vessels. Semin Thromb Hemost 14:285, 1988.

Harker LA , Kelly AB , Hanson SR , Krupski W. , Bass A. , Osterud B. , FitzGerald GA , Goodnight SH , Conner WE Interruption of vascular thrombus formation and vascular lesion formation by dietary n-3 fatty acids in fish oil in nonhuman primates. Circulation 87: 1017, 1993.

Goodnight SH , Cairns JA , Fisher M. , Fitzgerald GA Assessment of the therapeutic use of n-3 fatty acids in vascular disease and thrombosis . Chest 102:374, 1992.